Skip to main content

Table 1 USP39 expression and patient characteristics of Zhao Renal dataset

From: USP39 promotes malignant proliferation and angiogenesis of renal cell carcinoma by inhibiting VEGF-A165b alternative splicing via regulating SRSF1 and SRPK1

  No. Pts No. USP39 p Value
Low High
Overall: n (%) 176 (100.0) 88 (50.0) 88 (50.0) 0.286a
 Male 101 (57.4) 47 (26.7) 54 (30.7)
 Female 75 (42.6) 41 (23.3) 34 (19.3)
Mean patient age, y (range) 65.2 (34–85) 63.7(42–85) 66.6 (34–85) < 0.000b
WHO performance status: n (%)     0.146a
 0 65 (36.9) 29 (16.5) 36 (20.5)
 1 63 (35.8) 35 (19.9) 28 (15.9)
 2 37 (21.0) 16 (9.1) 21 (11.9)
 3 10 (5.7) 8 (4.5) 2 (1.1)
 4 1 (0.6) 0 (0.0) 1 (0.6)
TNM stage: n (%)     0.919a
 I 49 (27.8) 25 (14.2) 24 (13.6)
 II 29 (16.5) 16 (9.1) 13 (7.4)
 III 40 (22.7) 19 (10.8) 21 (11.9)
 IV 58 (33.0) 28 (15.9) 30 (17.0)
Fuhrman grade: n (%)     0.726a
 1 9 (5.1) 6 (3.4) 3 (1.7)
 2 34 (19.3) 18 (10.2) 16 (9.1)
 3 93 (52.8) 45 (25.6) 48 (27.3)
 4 40 (22.7) 19 (10.8) 21 (11.9)
Patient outcome: n (%)     0.008a
 Died 111 (63.1) 47 (21.6) 64 (27.3)
 Alive 65 (36.9) 41 (4.0) 24 (1.1)
Median OS, mo (95% CI) 39 (33.4–44.6) 59 (14.1–103.9) 35 (23.0–47.0) 0.006c
  1. Analysis of USP39 in the ONCOMINE gene database. The expression level of USP39 was positively correlated with the survival rate of renal cancer patients
  2. aChi-square test
  3. bWilcoxon rank sum test
  4. cLog rank test